Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

67.51USD
24 Mar 2017
Change (% chg)

$0.02 (+0.03%)
Prev Close
$67.49
Open
$67.57
Day's High
$67.87
Day's Low
$67.20
Volume
6,037,791
Avg. Vol
10,104,620
52-wk High
$103.10
52-wk Low
$65.38

GILD.O

Chart for GILD.O

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $88,240.09
Shares Outstanding(Mil.): 1,307.07
Dividend: 0.52
Yield (%): 3.08

Financials

  GILD.O Industry Sector
P/E (TTM): 6.79 47.98 29.94
EPS (TTM): 9.94 -- --
ROI: 30.47 -2.56 13.01
ROE: 72.16 5.14 14.16

BRIEF-Gilead Sciences lists EPCLUSA on public drug plan to treat chronic hepatitis C infection

* British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C infection Source text for Eikon: Further company coverage:

Mar 21 2017

BRIEF-Gilead Sciences says EPCLUSA added to Liste des médicaments de la RAMQ

* EPCLUSA, to treat all six genotypes of chronic Hepatitis C infection, added to Liste des médicaments de la RAMQ Source text for Eikon: Further company coverage:

Mar 20 2017

BRIEF-Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

* announces two new phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease

Mar 10 2017

Gilead seeks to overturn $2.54 bln verdict in hepatitis C drug case

Gilead Sciences Inc has asked a federal judge to overturn a record $2.54 billion jury verdict in a patent infringement lawsuit by rival Merck & Co Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

Feb 27 2017

BRIEF-Gilead receives approval in Canada for Odefsey for treatment of HIV-1 infection

* Gilead receives approval in Canada for Odefsey for the treatment of HIV-1 infection Source text for Eikon: Further company coverage:

Feb 16 2017

BRIEF-Gilead announces 144-week data evaluating safety and efficacy of Genvoya

* Gilead announces 144-week data evaluating safety and efficacy of Genvoya for treatment of HIV-1 in treatment-naïve adults

Feb 14 2017

Gilead challenges GSK with strong HIV drug data

LONDON Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

Gilead challenges GSK with strong HIV drug data

LONDON, Feb 14 Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

BRIEF-Gilead presents new phase 2 data on Bictegravir

* Gilead presents new phase 2 data on Bictegravir, an investigational integrase strand transfer inhibitor for the treatment of HIV

Feb 13 2017

BRIEF-Gilead announces findings from new preclinical study evaluating novel class of HIV Capsid inhibitors

* Gilead announces findings from new preclinical study evaluating novel class of HIV Capsid inhibitors

Feb 13 2017

More From Around the Web

Competitors

Earnings vs. Estimates